BioScrip (NASDAQ: BIOS) reported Q4 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $240.1 million versus the consensus estimate of $235.68 million.

GUIDANCE:

BioScrip sees FY2017 revenue of $920-950 million, versus the consensus of $952 million.

For earnings history and earnings-related data on BioScrip (BIOS) click here.